Although serum IgE does not reliably track disease severity or therapeutic response, anti-IgE monoclonal antibodies are approved for patients with persistent atopy, particularly children with allergic asthma and adults who also suffer from allergic rhinitis, chronic sinusitis, nasal polyposis, or chronic urticaria [79]. Here, IGHE is linked to chronic rhinosinusitis.